

Reinhold Schäfer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1414262/publications.pdf>

Version: 2024-02-01

35
papers

2,091
citations

394390

19
h-index

454934

30
g-index

35
all docs

35
docs citations

35
times ranked

4063
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutation-specific effects of NRAS oncogenes in colorectal cancer cells. <i>Advances in Biological Regulation</i> , 2021, 79, 100778.	2.3	4
2	Generation of Patient-Derived Colorectal Cancer Organoids for RAS Studies. <i>Methods in Molecular Biology</i> , 2021, 2262, 349-360.	0.9	2
3	Rapid testing of candidate oncogenes and tumour suppressor genes in signal transduction and neoplastic transformation. <i>Advances in Biological Regulation</i> , 2021, , 100841.	2.3	2
4	SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells. <i>Cell Reports</i> , 2020, 32, 108184.	6.4	19
5	Reduced replication origin licensing selectively kills KRAS-mutant colorectal cancer cells via mitotic catastrophe. <i>Cell Death and Disease</i> , 2020, 11, 499.	6.3	4
6	Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer. <i>Cells</i> , 2019, 8, 713.	4.1	32
7	Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. <i>PLoS Genetics</i> , 2019, 15, e1008076.	3.5	59
8	Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 569-581.	5.1	19
9	Efficacy of a structured workflow for the interpretation of comprehensive genomic analysis data in clinical routine.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24164-e24164.	1.6	1
10	DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. <i>Nature Communications</i> , 2017, 8, 14093.	12.8	85
11	Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. <i>Nature Communications</i> , 2017, 8, 14262.	12.8	260
12	Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells. <i>Cell Reports</i> , 2017, 21, 2813-2828.	6.4	105
13	Is the primary tumor location (PTL) associated with differential gene expression profiles in patients with metastatic colorectal cancer (mCRC)? Analysis of the FIRE1-trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 598-598.	1.6	4
14	Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC). <i>Cytokine</i> , 2016, 85, 157-164.	3.2	13
15	Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 300-319.	7.4	89
16	Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. <i>Journal of Biomolecular Screening</i> , 2016, 21, 931-941.	2.6	112
17	Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances: Data of the FIRE-1 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 562-562.	1.6	0
18	Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 13334-13346.	1.8	19

#	ARTICLE	IF	CITATIONS
19	Ras-Mediated Deregulation of the Circadian Clock in Cancer. <i>PLoS Genetics</i> , 2014, 10, e1004338.	3.5	140
20	Abstract 2978: Generation of drug response data from 57 new patient-derived colon cancer xenografts and 3D cell cultures for systematic correlation with tumor biology within the OncoTrack* project. , 2014, , .		2
21	The Nerve Growth Factor Receptor CD271 Is Crucial to Maintain Tumorigenicity and Stem-Like Properties of Melanoma Cells. <i>PLoS ONE</i> , 2014, 9, e92596.	2.5	80
22	Network quantification of EGFR signaling unveils potential for targeted combination therapy. <i>Molecular Systems Biology</i> , 2013, 9, 673.	7.2	158
23	Identifying resistance biomarkers against five clinically approved tyrosine kinase inhibitors in 45 cell lines.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21005-e21005.	1.6	0
24	RAS oncogene-mediated deregulation of the transcriptome: From molecular signature to function. <i>Advances in Enzyme Regulation</i> , 2011, 51, 126-136.	2.6	9
25	Identification of Y-Box Binding Protein 1 As a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer Cells. <i>PLoS Genetics</i> , 2010, 6, e1001231.	3.5	80
26	A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase-6 shapes extracellular signal-related kinase activity in RAS-transformed fibroblasts. <i>FEBS Journal</i> , 2009, 276, 1024-1035.	4.7	52
27	<i>HMG2</i> gene is a promising target for ovarian cancer silencing therapy. <i>International Journal of Cancer</i> , 2008, 123, 348-356.	5.1	102
28	Functional transcriptomics: An experimental basis for understanding the systems biology for cancer cells. <i>Advances in Enzyme Regulation</i> , 2007, 47, 41-62.	2.6	0
29	Oncogenic Signaling Pathways and Deregulated Target Genes. , 2007, 176, 7-24.		6
30	Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. <i>International Journal of Cancer</i> , 2006, 118, 1699-1712.	5.1	133
31	Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. <i>Oncogene</i> , 2004, 23, 4536-4555.	5.9	76
32	Gene expression profiling of advanced lung cancer. <i>International Journal of Cancer</i> , 2000, 86, 512-517.	5.1	31
33	A genome-wide survey of RAS transformation targets. <i>Nature Genetics</i> , 2000, 24, 144-152.	21.4	265
34	Gene expression profiling of fibroblasts resistant toward oncogene-mediated transformation reveals preferential transcription of negative growth regulators. <i>Oncogene</i> , 1999, 18, 5448-5454.	5.9	25
35	Growth-inhibitory Activity and Downregulation of the Class II Tumor-suppressor Gene H-rev107 in Tumor Cell Lines and Experimental Tumors. <i>Journal of Cell Biology</i> , 1997, 136, 935-944.	5.2	103